Nynomic (M7U) H1 2026 earnings summary

Executive summary

• Revenue rose 13% year-over-year to €47.7 million in H1 2026, driven by strong demand in core markets and a 46% increase in order backlog to €63.5 million.

• EBIT improved significantly to €1.8 million from -€2.0 million, reflecting efficiency gains from the NyFIT2025 program and higher sales.

• Cash flow from operations turned positive at €2.2 million, and EPS before minorities rose to €0.15 from -€0.50.

• The company remains focused on innovation in photonics, targeting sustainable growth across Clean Tech, Life Science, and Green Tech segments.

Financial highlights

• Revenue: €47.7 million (+13% YoY); EBIT: €1.8 million (up from -€2.0 million); EBIT margin: 3.8%.

• EBITDA: €4.8 million (+508% YoY); investments: €2.1 million (+59% YoY); cash flow from operations: €2.2 million (up from -€1.3 million).

• EPS before minorities: €0.15 (up from -€0.50); net income: €1.0 million (up from -€3.3 million).

• Equity ratio: 76% (up from 75.2% at year-end 2025); net cash position: €9.4 million.

Outlook and guidance

• Full-year 2026 guidance confirmed: revenue between €100–105 million and EBIT margin of 6–8%.

• Management expects further operational improvement in H2 2026, supported by a strong order backlog and ongoing efficiency measures.

• Mid-term targets: average annual revenue growth of ~10% and stable EBIT margin above 15%.